CD33 and sarcoma: Decrease in the Lin−/CD11b+/CD33+ monocyte subset was significantly correlated with improved PFS, which was also seen in other cancer settings [17], [19], and was a particularly suppressive subset examined in renal cell carcinoma and sarcoma patients [34].